



## Drug Utilization Review Board Meeting Minutes September 12, 2023

DUR Board Members in attendance:

In person: Tim Bourke, R.P., Robert Wergin, M.D.

Virtual: Jennifer Meyfeldt, M.D., Charlie Moore, R.P., Dave Randolph, R.P.

DUR Board Members not in attendance: Tom Dunn, R.P.

Nebraska Medicaid & LTC attendees in person: Carisa Schweitzer Masek, R.P., Deputy Director Population Health; Leah Spencer, R.N., Program Specialist; Dianne Garside, R.P.  
Virtual: Spencer Moore, R.P.

Contracted attendees in person: Gerette Augusta, R.P., Healthy Blue Nebraska; Jamie Benson, R.P., Nebraska Total Care.

Virtual: Elanah Figueroa, Account Manager, Magellan RX Management; Jenni Pandak, Sr. Director, Magellan RX Management; Nikia Bennette-Carter, R.P., Magellan Rx Management.

Public visitors in attendance in person: Randall Roth, Merck; Karen Malamut, D.O., Merck.  
Other virtual attendees.

### **I. Opening and Introductions**

The meeting was called to order by Carisa Schweitzer Masek. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the Open-Meetings Act was available.

### **II. Conflict of Interest or changes**

No changes in conflict of interest were declared.

### **III. Agenda approval**

The Agenda was unanimously approved.

### **IV. Approval of Minutes from DUR Board July 2023 meeting.**

The minutes were unanimously approved.

### **V. Update on Recommendations from previous meeting(s)**

No updates.

## **VI. Special Topics:**

### **A. PHE Unwind update**

Carisa Schweitzer Masek provided an update on the end of the public health emergency (PHE) unwind. She directs that further questions can be directed to the State.

### **B. Opvee and generic naloxone and Division of Public Health naloxone program overview**

Indications and criteria for Opvee and naloxone OTC were presented as new medications. Garside reviews medications and indications. Opvee is placed on the PDL as non-preferred as it has not yet been reviewed by the P&T. OTC Narcan is noted to not be available as of this date.

Schweitzer Masek provides information on Opioid withdrawal and reversal agents versus Nebraska DHHS Division of Behavioral Health and Public Health departments.

## **VII. Retrospective DUR:**

### **A. Old Business- none**

### **B. New Business:**

The State provided utilization and reimbursement costs for hepatitis C drug therapy. It was verified that State assessment of the data shows member treatment courses were generally noted to be fully completed.

## **VIII. Prospective DUR**

### **A. Old Business- none**

### **B. New Business-**

Schweitzer Masek shares that Support Act data will be presented at the next meeting and share that new COVID vaccines will not be government supplied and at no copay for Medicaid members. It will be distributed through Vaccine for Childrens program for Medicaid members 18 and younger. There was discussion on COVID vaccine reimbursement and guidance from CMS.

## **IX. Future Meeting Date**

The next meeting is scheduled for November 14<sup>th</sup>, 2023.

## **X. Concerns & Comments**

### **Board:**

Wergin shares information on the Gold Card as an award to providers who prescribe certain medications and recommends this program be applied to the managed care organized as well as fee-for-service Medicaid. The gold card is proposed to waive prior authorization requirements.

Charlie Moore questions the State as to what pharmacies can be enrolled as a pharmacy who can be a provider and bill for prescriptions for NE Medicaid patients.

**DUR Director and State representatives: None**

**Magellan representatives: None**

**Managed Care Organization (MCO) representatives: None**

**Public attendees: None**

**XI. Adjournment**

The motion to adjourn the meeting was unanimously approved. The meeting was adjourned by Schweitzer Masek at 7:38 p.m.